Entrada Therapeutics, Inc.

NASDAQ:TRDA

Biotechnology

Healthcare
$4.96 +0.37%

+$0.03 today

Market cap
$194.19M
Beta
-0.26
P/E (TTM)
-1.7
EPS (TTM)
-$3.97
52W Low $4.93High $16.45

Volume 0.43M

Average 0.36M

TRDA Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Entrada Therapeutics, Inc.NASDAQ: TRDA

Operating Margin · Q1 FY2026 · quarter ended Mar 2026

Operating margin narrows to -4834.6%

Operating margin was -4834.6% in Q1 FY2026, down 4728.6 pp from a year earlier. On a trailing-twelve-month basis it was -3109.3%, down 3111.7 pp year over year.

Context

  • Operating margin widened in 1 of the last 2 fiscal years.
  • FY2025 was the lowest level in the 3 fiscal years shown.

What to watch

Whether operating margin reaches the consensus estimate from 4 analysts of -4123.9% for the fiscal year ending Dec 2026, down from -613.7% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-4834.6%-1585.4 pp QoQ
Last fiscal yearDec 2025
-613.7%-636.0 pp YoY
LTMMar 2026
-3109.3%-3111.7 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-4728.6 pp+412.6 pp+5141.2 pp
1 year-636.0 pp-3510.3 pp-2874.3 pp
3 years—-589.4 pp—
5 years+524.4 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-613.7%
Year-over-year change
-636.0pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How TRDA compares with its peers on the latest reported figures

  • TRDA's LTM Mar 2026 operating margin of -3109.3% is the 4th highest of the 5 companies compared; the peer median is -272.9%.
  • Its year-over-year change of -3111.7 pp is the 4th highest of 5, against a peer median of -166.6 pp.
TRDA Competitors Peer median
Operating Margin for TRDA and competitors
Company Period LTM level YoY 3-year change
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026-73.6% -35.9 pp-72.4 pp
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-196.7% -136.0 pp-117.4 pp
VYGRVoyager Therapeutics, Inc.LTM Mar 2026-349.2% -197.1 pp-202.3 pp
TRDAEntrada Therapeutics, Inc.LTM Mar 2026-3109.3% -3111.7 pp—
HUMAHumacyte, Inc.LTM Mar 2026-5649.2% -4216.0 pp+132.7 pp
ACHVAchieve Life Sciences, Inc.FY2025— ——
CAPRCapricor Therapeutics, Inc.FY2025— ——
AVIRAtea Pharmaceuticals, Inc.FY2025— ——
SGMTSagimet Biosciences Inc.FY2025— ——
ALLOAllogene Therapeutics, Inc.FY2025— ——
IMRXImmuneering CorporationFY2025— ——
Peer median (excluding TRDA) -272.9%-166.6 pp-94.9 pp

Competitors are the stored peer set for TRDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00129.01M210.78M25.42M
Cost of Revenue00004.1M
Gross Profit00129.01M210.78M21.33M
Gross Margin——100.0%100.0%83.9%
Research & Development35.93M66.61M99.88M125.31M142.27M
Selling, General & Admin15.2M30.64M32.29M38.47M41.05M
Operating Expenses51.13M97.25M132.18M163.77M177.32M
Depreciation & Amortization1.12M1.9M2.84M3.77M425K
EBITDA(50.04M)(90.09M)14.9M70.26M(142.4M)
EBITDA Margin——11.5%33.3%-560.2%
Operating Income(51.13M)(97.25M)(3.16M)47.01M(156M)
Operating Margin——-2.5%22.3%-613.7%
Interest Income02.63M15.22M19.47M0
Interest Expense02.63M000
Other Income / Expenses(31K)2.63M15.22M19.47M13.17M
Income Before Tax(51.16M)(94.62M)12.06M66.49M(142.83M)
Pre-Tax Margin——9.3%31.5%-561.8%
Income Tax Expense0018.74M859K924K
Net Income(51.16M)(94.62M)(6.69M)65.63M(143.75M)
Net Margin——-5.2%31.1%-565.5%
EPS (Basic)(1.60)(2.79)(0.20)1.76(3.47)
EPS (Diluted)(1.60)(2.79)(0.20)1.68(3.47)
Weighted Avg Shares31.22M31.29M33.05M37.31M41.37M
Weighted Avg Shares (Diluted)31.22M31.29M33.05M39M41.37M

Entrada Therapeutics, Inc.

NASDAQ:TRDA

Intrinsic Alpha fair value

Locked

Current Price

$4.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.